KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2025)

Historic Receivables - Other for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $21.9 million.

  • Recursion Pharmaceuticals' Receivables - Other rose 29836.36% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 29836.36%. This contributed to the annual value of $49.2 million for FY2024, which is 148907.56% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Receivables - Other of $21.9 million as of Q3 2025, which was up 29836.36% from $21.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Receivables - Other's 5-year high stood at $49.2 million during Q4 2024, with a 5-year trough of $2.1 million in Q1 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' median Receivables - Other value was $5.5 million (recorded in 2024), while the average stood at $10.0 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first plummeted by 8189.74% in 2023, then skyrocketed by 148907.56% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Receivables - Other stood at $9.1 million in 2021, then plummeted by 69.6% to $2.8 million in 2022, then increased by 12.39% to $3.1 million in 2023, then soared by 1489.08% to $49.2 million in 2024, then plummeted by 55.44% to $21.9 million in 2025.
  • Its Receivables - Other was $21.9 million in Q3 2025, compared to $21.6 million in Q2 2025 and $6.2 million in Q1 2025.